# Janux Therapeutics Inc. (JANX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $20.24, market value $1.2 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Janux Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 51.6×**. Each dollar of revenue is priced at 51.6×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 1.3×**. The shares trade at 1.3× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -3.4%** (5-yr avg -7.1%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -598.1%**. Operating margin is negative: the business loses money before interest and tax.
- **Return on equity: -11.9%**. Return on equity is negative because earnings are negative.
- **Return on assets: -10.2%**. Each dollar of assets produces -10.2% of profit.

## Growth
- **Revenue growth (1 yr): -5.6%** (3-yr 5.1%/yr). Revenue fell 5.6% over the last year.
- **EPS growth (1 yr): -43.0%**. Earnings per share fell 43.0%, slower than revenue, so margins compressed.

## Financial health
- **Current ratio: 39.04** (quick 39.04). Current assets cover the next year's liabilities 39.04 times.
- **Altman Z-score: 18.56**. A Z-score of 18.56 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Janux Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (17 analysts). 17 analysts cover Janux Therapeutics Inc.; the consensus is strong_buy, with an average price target of $36.24 (+79% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -15.5%** (YTD 46.7%, 3-mo 51.5%). The shares are down 15.5% over twelve months including dividends.
- **From 52-week high: -42.7%** (67.0% above the low). Trading 43% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 75**. An RSI of 75 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 1.10** (volatility 74%). Beta of 1.10 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=JANX · Page: https://foliofundamentals.com/stocks/janx

Not investment advice.